Shared Care: Patient-Centered Management After Hematopoietic Cell Transplantation



Status:Recruiting
Healthy:No
Age Range:18 - Any
Updated:3/10/2019
Start Date:January 1, 2018
End Date:December 31, 2022
Contact:Gregory A. Abel, MD, MPH
Email:Gregory_Abel@dfci.harvard.edu
Phone:617-632-2304

Use our guide to learn which trials are right for you!

This research study aims to evaluate the effectiveness of allowing patients who have had a
hematopoietic cell transplant to receive some of their post-transplant care with a local
oncologist rather than returning to the transplant center for all of their follow-up.

Hematopoietic Cell Transplantation (HCT) - also known as bone marrow transplant - is only
available at select centers in the United States which can collect and store stem cells, as
well as care for patients before their new immune system cells take hold. For this reason,
many patients who undergo HCT live at great distances from their HCT center. Also, after
hospital discharge, the first 180 days post-HCT are very important, as patients must be
managed closely with frequent follow-up visits.

A potential way to make life easier for HCT patients is to allow some of the post-transplant
care to be provided by local oncologists who practice closer to where patients live. This
could reduce the burden on patients and their caregivers; however, it is not known if a
shared care model would ultimately benefit them. The investigators want to assess the
effectiveness of a Shared Care program which allows patients to receive half of their
post-HCT care at the HCT center, and the other half with their local oncologist

Inclusion Criteria:

- Age >= 18 years of age

- Scheduled to receive an allogeneic HCT at the Dana-Farber Inpatient Hospital or BWH
under the care of a DFCI physician

- Residence in New York, Maine, New Hampshire, Vermont, Connecticut, or Massachusetts

- Referred from or live less than 1 hour from one of the local participating centers.

- Ability to read English (to fill out standard QOL forms)

Exclusion Criteria:

- Age <18 years of age

- Scheduled to receive an autologous HCT

- Has received an allogeneic transplant in the past; scheduled to receive a second
allogeneic transplant

- Did not receive an allogeneic HCT at Dana-Farber

- Does not live in New York, Maine, New Hampshire, Vermont, Connecticut, or
Massachusetts
We found this trial at
9
sites
489 State St
Bangor, Maine 04401
(207) 973-7000
Eastern Maine Medical Center Located in Bangor, Eastern Maine Medical Center (EMMC) serves communities throughout...
?
mi
from
Bangor, ME
Click here to add this to my saved trials
Albany, New York 12206
?
mi
from
Albany, NY
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Gregory A. Abel, MD MPH
Phone: 617-632-2304
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Brunswick, Maine 04011
Principal Investigator: Christian Thomas, MD
Phone: 207-396-7634
?
mi
from
Brunswick, ME
Click here to add this to my saved trials
Londonderry, New Hampshire 03053
?
mi
from
Londonderry, NH
Click here to add this to my saved trials
Milford, Massachusetts 01757
Principal Investigator: Michael Constantine, MD
Phone: 508-488-3700
?
mi
from
Milford, MA
Click here to add this to my saved trials
Providence, Rhode Island 02903
?
mi
from
Providence, RI
Click here to add this to my saved trials
Stamford, Connecticut 06904
?
mi
from
Stamford, CT
Click here to add this to my saved trials
Weymouth, Massachusetts 02190
Principal Investigator: Meredith Faggen, MD
Phone: 781-624-4800
?
mi
from
Weymouth, MA
Click here to add this to my saved trials